T2	outcome-Measure 593 653	pathologic complete remission (pCR) in the breast and axilla
T3	total-participants 836 838	56
T4	intervention-participants 881 883	29
T5	control-participants 910 912	27
T6	outcome 948 972	pCR in the breast/axilla
T7	outcome 1129 1132	pCR
T8	cv-bin-percent 1134 1137	41%
T9	iv-bin-percent 1142 1145	69%
T10	outcome 1248 1257	effective
T14	cv-bin-percent 1461 1464	67%
T15	iv-bin-percent 1469 1472	71%
T16	outcome 1492 1524	luminal-B (HER2-positive) tumors
T17	cv-bin-percent 1605 1608	21%
T18	iv-bin-percent 1613 1616	62%
T11	outcome 1398 1407	pCR rates
T13	control 885 904	every-3-weeks group
T1	intervention 0 49	Weekly paclitaxel/carboplatin/trastuzumab therapy
